131 related articles for article (PubMed ID: 35918067)
1. Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade.
Kobayashi T; Iwama S; Yamagami A; Yasuda Y; Okuji T; Ito M; Zhou X; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Hase T; Morise M; Ito T; Kikumori T; Inoue M; Ando Y; Masuda N; Kawashima H; Hashimoto N; Arima H
J Clin Endocrinol Metab; 2022 Sep; 107(10):e4115-e4123. PubMed ID: 35918067
[TBL] [Abstract][Full Text] [Related]
2. Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline.
Zhou X; Iwama S; Kobayashi T; Ando M; Arima H
J Clin Endocrinol Metab; 2023 Sep; 108(10):e1056-e1062. PubMed ID: 37084392
[TBL] [Abstract][Full Text] [Related]
3. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab.
Kimbara S; Fujiwara Y; Iwama S; Ohashi K; Kuchiba A; Arima H; Yamazaki N; Kitano S; Yamamoto N; Ohe Y
Cancer Sci; 2018 Nov; 109(11):3583-3590. PubMed ID: 30230649
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
5. Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade.
Yamagami A; Iwama S; Kobayashi T; Zhou X; Yasuda Y; Okuji T; Ito M; Izuchi T; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Arima H
Endocr J; 2024 Apr; ():. PubMed ID: 38599854
[TBL] [Abstract][Full Text] [Related]
6. Thyroid Dysfunction Related to the Antiangiogenic VEGFR2-Binding Monoclonal Antibody Ramucirumab: A Series of 14 Cases and a Descriptive Study.
Dote S; Yamaguchi D; Hira D; Noda S; Kobayashi Y; Terada T
Biol Pharm Bull; 2020; 43(4):752-756. PubMed ID: 32238718
[TBL] [Abstract][Full Text] [Related]
7. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
8. Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline.
Iwama S; Kobayashi T; Yasuda Y; Okuji T; Ito M; Ando M; Zhou X; Yamagami A; Onoue T; Kawaguchi Y; Miyata T; Sugiyama M; Takagi H; Hagiwara D; Suga H; Banno R; Hase T; Morise M; Wakahara K; Yokota K; Kato M; Nishio N; Tanaka C; Miyata K; Ogura A; Ito T; Sawada T; Shimokata T; Niimi K; Ohka F; Ishigami M; Gotoh M; Hashimoto N; Saito R; Kiyoi H; Kajiyama H; Ando Y; Hibi H; Sone M; Akiyama M; Kodera Y; Arima H
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1620-e1630. PubMed ID: 34791304
[TBL] [Abstract][Full Text] [Related]
9. Association of Thyroid Peroxidase Antibodies and Thyroglobulin Antibodies with Thyroid Function in Pregnancy: An Individual Participant Data Meta-Analysis.
Bliddal S; Derakhshan A; Xiao Y; Chen LM; Männistö T; Ashoor G; Tao F; Brown SJ; Vafeiadi M; Itoh S; Grineva EN; Taylor P; Ghafoor F; Vaidya B; Hattersley A; Mosso L; Oken E; Kishi R; Alexander EK; Maraka S; Huang K; Chaker L; Bassols J; Pirzada A; López-Bermejo A; Boucai L; Peeters RP; Pearce EN; Nelson SM; Chatzi L; Vrijkotte TG; Popova PV; Walsh JP; Nicolaides KH; Suvanto E; Lu X; Pop VJM; Forman JL; Korevaar TIM; Feldt-Rasmussen U
Thyroid; 2022 Jul; 32(7):828-840. PubMed ID: 35596568
[No Abstract] [Full Text] [Related]
10. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
de Filette J; Jansen Y; Schreuer M; Everaert H; Velkeniers B; Neyns B; Bravenboer B
J Clin Endocrinol Metab; 2016 Nov; 101(11):4431-4439. PubMed ID: 27571185
[TBL] [Abstract][Full Text] [Related]
11. Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex.
Mammen JS; Ghazarian SR; Pulkstenis E; Subramanian GM; Rosen A; Ladenson PW
J Clin Endocrinol Metab; 2012 Sep; 97(9):3270-6. PubMed ID: 22689690
[TBL] [Abstract][Full Text] [Related]
12. Effects of thyroid status on thyroid autoimmunity expression in euthyroid and hypothyroid patients with Hashimoto's thyroiditis.
Rieu M; Richard A; Rosilio M; Laplanche S; Ropion V; Fombeur JP; Berrod JL
Clin Endocrinol (Oxf); 1994 Apr; 40(4):529-35. PubMed ID: 8187321
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Delivanis DA; Gustafson MP; Bornschlegl S; Merten MM; Kottschade L; Withers S; Dietz AB; Ryder M
J Clin Endocrinol Metab; 2017 Aug; 102(8):2770-2780. PubMed ID: 28609832
[TBL] [Abstract][Full Text] [Related]
14. Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events.
Muir CA; Wood CCG; Clifton-Bligh RJ; Long GV; Scolyer RA; Carlino MS; Menzies AM; Tsang VHM
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1843-e1849. PubMed ID: 35104870
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer.
Wu X; Lun Y; Jiang H; Gang Q; Xin S; Duan Z; Zhang J
Endocrine; 2014 Aug; 46(3):554-60. PubMed ID: 24338678
[TBL] [Abstract][Full Text] [Related]
16. BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION.
Pollack RM; Kagan M; Lotem M; Dresner-Pollak R
Endocr Pract; 2019 Aug; 25(8):824-829. PubMed ID: 31013164
[No Abstract] [Full Text] [Related]
17. Immune checkpoint inhibitor-related thyroid dysfunction.
Iwama S; Kobayashi T; Yasuda Y; Arima H
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
[TBL] [Abstract][Full Text] [Related]
18. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
[TBL] [Abstract][Full Text] [Related]
19. Immune-related thyroid dysfunctions during anti PD-1/PD-L1 inhibitors: new evidence from a single centre experience.
Nervo A; Ferrari M; Gruosso G; Migliore E; Basile S; D'Angelo V; Roux A; Piovesan A; Arvat E
Clin Exp Med; 2023 Dec; 23(8):4817-4824. PubMed ID: 37103651
[TBL] [Abstract][Full Text] [Related]
20. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
